ATNM — Actinium Pharmaceuticals, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1388320 ·
Last close
$1.35
Market Cap
$42.45M
52W High
$1.72
52W Low
$0.74
ADV30
245,620
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -6,122,000 | -5,843,000 | 32,465,000 | 28,677,000 | 7,880,000 |
| Jun 2026 | 35,000,000 | — | 27,565,000 | 27,901,000 | 40,157,000 | 36,473,000 | 9,855,000 |
| Mar 2026 | 0 | — | -5,903,000 | -5,522,000 | 45,438,000 | 42,132,000 | 43,134,000 |
| Dec 2025 | 0 | — | -6,414,000 | -5,940,000 | 51,775,000 | 47,998,000 | 43,941,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,663,000
Investing CF
$-584,000
Financing CF
$-217,000
CapEx
$-480,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.33
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-387,334,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$9,556,000
Pretax Income TTM
$11,308,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,090,000
EBITDA
$9,791,000
Free Cash Flow
$7,143,500
Enterprise Value
$8,886,010
Total Cash
$36,473,000
Total Debt
$1,341,000
Shares Out
31,441,436
Trailing EPS
$0.35
Book Value
$0.96
ROE
45.9%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 90,000 | -36,247,000 | -33,887,000 | 51,775,000 | 43,941,000 | 7,834,000 | -24,580,000 |
| Dec 2024 | 0 | -42,121,000 | -38,243,000 | 76,899,000 | 44,141,000 | 32,758,000 | -33,072,000 |
| Dec 2023 | 81,000 | -51,920,000 | -48,818,000 | 81,445,000 | 45,066,000 | 36,379,000 | -47,335,000 |
| Dec 2022 | 1,030,000 | -34,104,000 | -33,017,000 | 114,192,000 | 47,711,000 | 66,481,000 | 8,644,000 |
TTM Snapshot
Revenues TTM
$34,146,000
NetIncome TTM
$11,308,000
OpCashFlow TTM
—
Assets (Latest)
$40,157,000
Forward EPS
$-0.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HYFT | MindWalk Holdings Corp. | $42.60M | $0.91 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $41.88M | $0.69 | — |
| TLPH | TALPHERA, INC. | $41.61M | $0.80 | — |
| DWTX | Dogwood Therapeutics, Inc. | $41.29M | $1.08 | — |
| PRNAF | ALTERITY THERAPEUTICS LTD | $43.70M | $0.20 | — |
News headlines (Yahoo Finance, 1h cache)
Actinium: Q3 Earnings Snapshot
2026-11-16 22:55 · Yahoo
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy
2026-11-12 13:00 · Yahoo
Patient enrolment begins in Actinium’s RADIANZ solid tumour trial
2026-11-12 11:08 · Yahoo
Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy
2026-11-11 13:00 · Yahoo
ATNM: Introducing ATNM-400's HER3 Target
2026-11-09 17:00 · Yahoo
Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development
2026-11-09 13:00 · Yahoo
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
2026-11-04 14:11 · Yahoo
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
2026-11-04 14:05 · Yahoo
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
2026-11-02 13:00 · Yahoo
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
2026-10-30 21:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.